Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)

Expanded access is currently available for this treatment.
Verified April 2016 by Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: March 7, 2014
Last updated: April 22, 2016
Last verified: April 2016